About Primrose Therapeutics
Primrose Therapeutics is a company based in New York (United States) founded in 2010 was acquired by StemlineTherapeutics in September 2011.. Primrose Therapeutics has raised $752.55 thousand across 1 funding round from investors including Stemline Therapeutics. Primrose Therapeutics operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Primrose Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$752.55 K (USD)
in 1 rounds
-
Latest Funding Round
$752.55 K (USD), Seed
Jul 30, 2010
- Investors
-
Employee Count
Employee Count
-
Acquired by
StemlineTherapeutics
(Sep 01, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Primrose Therapeutics
Primrose Therapeutics has successfully raised a total of $752.55K through 1 strategic funding round. The most recent funding activity was a Seed round of $752.55 thousand completed in July 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $752,550
-
First Round
First Round
(30 Jul 2010)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2010 | Amount | Seed - Primrose Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Primrose Therapeutics
Primrose Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Stemline Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Novel oncology therapeutics targeting cancer stem cells are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Primrose Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Primrose Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Primrose Therapeutics Comparisons
Competitors of Primrose Therapeutics
Primrose Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Primrose Therapeutics
When was Primrose Therapeutics founded?
Primrose Therapeutics was founded in 2010.
Where is Primrose Therapeutics located?
Primrose Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Is Primrose Therapeutics a funded company?
Primrose Therapeutics is a funded company, having raised a total of $752.55K across 1 funding round to date. The company's 1st funding round was a Seed of $752.55K, raised on Jul 30, 2010.
What does Primrose Therapeutics do?
Primrose Therapeutics was founded in 2010 in New York, United States, as a biotechnology company. Focus is placed on developing treatments for Polycystic Kidney Disease (PKD), a condition that shortens average lifespan to 64 years without any FDA-approved therapies. Operations center on advancing potential solutions for this disease. Acquisition by Stemline Therapeutics occurred in September 2011.
Who are the top competitors of Primrose Therapeutics?
Primrose Therapeutics's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Who are Primrose Therapeutics's investors?
Primrose Therapeutics has 1 investor. Key investors include Stemline Therapeutics.